The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A multi-institutional study

European Urology

Volumn 65, Issue 1, 2014, Pages 227-234

  Tanaka, Nobuyuki ^a,d   Kikuchi, Eiji ^a   Shirotake, Suguru ^a,b   Kanao, Kent ^a   Matsumoto, Kazuhiro ^a,c   Kobayashi, Hiroaki ^a,f   Miyazaki, Yasumasa ^a,g   Ide, Hiroki ^a,h   Obata, Jun ^a   Hoshino, Katsura ^a   Hayakawa, Nozomi ^a,c   Ito, Yujiro ^a,d   Kosaka, Takeo ^a   Kodaira, Kiichiro ^b   Oyama, Masafumi ^b   Miyajima, Akira ^a   Momma, Tetsuo ^e   Nakagawa, Ken ^a   Ueno, Munehisa ^b   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c SAISEIKAI CENTRAL HOSPITAL   (Japan)

^d Saitama City Hospital   (Japan)

^e SAITAMA NATIONAL HOSPITAL   (Japan)

^f Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^g Ogikubo Hospital   (Japan)

^h Inagi City Hospital   (Japan)

Author keywords

C reactive protein; Outcome; Survival; Upper urinary tract; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADICAL NEPHROURETERECTOMY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; BLOOD; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEPHRECTOMY; PROCEDURES; PROGNOSIS; TUMOR RECURRENCE; URETERAL NEOPLASMS;

AGED; C-REACTIVE PROTEIN; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; URETERAL NEOPLASMS;

EID: 84888821956     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.11.050     Document Type: Article

References (30)

1. M. Rouprêt, R. Zigeuner, and J. Palou European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update Eur Urol 59 2011 584 594
2. V. Margulis, S.F. Shariat, S.F. Matin Upper Tract Urothelial Carcinoma Collaboration. The Upper Tract Urothelial Carcinoma Collaboration Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration Cancer 115 2009 1224 1233
3. E.K. Cha, S.F. Shariat, and M. Kormaksson Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma Eur Urol 61 2012 818 825
4. O. Kamihira, R. Hattori, and A. Yamaguchi Laparoscopic radical nephroureterectomy: a multicenter analysis in Japan Eur Urol 55 2009 1397 1409
5. D.R. Yates, V. Hupertan, P. Colin French collaborative national database on UUT-UC Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram Br J Cancer 106 2012 1083 1088
6. P. Colin, A. Ouzzane, and D.R. Yates Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival Ann Surg Oncol 19 2012 3613 3620
7. R. Zigeuner, S.F. Shariat, and V. Margulis Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract Eur Urol 57 2010 575 581
8. G. Lughezzani, M. Burger, and V. Margulis Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature Eur Urol 62 2012 100 114
9. D.J. McKeown, D.J. Brown, A. Kelly, A.M. Wallace, and D.C. McMillan The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer Br J Cancer 91 2004 1993 1995
10. K.H. Allin, S.E. Bojesen, and B.G. Nordestgaard Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer J Clin Oncol 27 2009 2217 2224
11. B.L. Pierce, R. Ballard-Barbash, and L. Bernstein Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients J Clin Oncol 27 2009 3437 3444
12. T.C. Chua, C.H. Chong, W. Liauw, J. Zhao, and D.L. Morris Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy Ann Surg 256 2012 342 349
13. G. Gakis, T. Todenhofer, and M. Renninger Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score BJU Int 108 2011 1800 1805
14. K. Saito, S. Kawakami, and Y. Ohtsuka The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically BJU Int 100 2007 269 273
15. D.G. Altman, B. Lausen, W. Sauerbrei, and M. Schumacher Dangers of using "optimal" cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 1994 829 835
16. M. Rink, H. Fajkovic, and E.K. Cha Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma Eur Urol 61 2012 854 855
17. J.A. Karam, Y. Lotan, and P.I. Karakiewicz Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy Lancet Oncol 8 2007 128 136
18. T. Kinoshita, H. Ito, and C. Miki Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma Cancer 85 1999 2526 2531
19. M. Okamoto, K. Hattori, and R. Oyasu Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro Int J Cancer 72 1997 149 154
20. S.H. Jee, S.C. Shen, H.C. Chiu, W.L. Tsai, and M.L. Kuo Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency Oncogene 20 2001 198 208
21. M. Trikha, R. Corringham, B. Klein, and J.F. Rossi Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence Clin Cancer Res 9 2003 4653 4665
22. O. Tredan, C.M. Galmarini, K. Patel, and I.F. Tannock Drug resistance and the solid tumor microenvironment J Natl Cancer Inst 99 2007 1441 1454
23. A. Mancino, and T. Lawrence Nuclear factor-kappaB and tumor-associated macrophages Clin Cancer Res 6 2010 784 789
24. D. Hanahan, and L.M. Coussens Accessories to the crime: functions of cells recruited to the tumor microenvironment Cancer Cell 21 2012 309 322
25. L. Zitvogel, O. Kepp, L. Galluzzi, and G. Kroemer Inflammasomes in carcinogenesis and anticancer immune responses Nat Immunol 13 2012 343 351
26. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
27. S.M. Weis, and D.A. Cheresh Tumor angiogenesis: molecular pathways and therapeutic targets Nat Med 17 2011 1359 1370
28. B. Andrews, S.F. Shariat, J.H. Kim, T.M. Wheeler, K.M. Slawin, and S.P. Lerner Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer J Urol 167 2002 1475 1481
29. S.F. Shariat, J. Kim, C. Nguyen, T.M. Wheeler, S.P. Lerner, and K.M. Slawin Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer Urology 61 2003 359 364
30. G. Gakis, T. Todenhofer, and A. Stenzl The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer Curr Opin Urol 21 2011 428 433